This federal Project Grant award of $616,588, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research, aims to illuminate environmental sensing mechanisms of the fungal pathogen Cryptococcus neoformans, which causes deadly fungal meningitis. The research team at the University of California, San Francisco (UCSF) will: Dissect the function of a new component of a conserved pH sensing pathway in C. neoformans. Dissect...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on exploring the genetic basis of two pathogenesis-relevant traits in the Cryptococcus fungal genus: thermotolerance and azole drug resistance. The $443,944 award, with a performance period from August 2024 to July 2029, will employ high-throughput genetic approaches to characterize genome-wide...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $515,875 to the University of Florida to conduct research on the mechanisms underlying Cryptococcus neoformans-induced meningoencephalitis and neurotoxicity in a CD4 T cell-deficient mouse model. The goal is to elucidate how the Cryptococcus polysaccharide capsule component glucuronoxylomannan (GXM) affects basal...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $232,073 Project Grant (R21AI186688) to The Research Foundation For The State University Of New York (Stony Brook University) to explore the host-pathogen dynamics between the fungal pathogen Cryptococcus neoformans (CN) and HIV in microglia, the predominant immune cells in the brain. The overarching goal is to investigate how the accumulation...
The National Institute of General Medical Sciences (NIGMS) awarded a $415,520 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to the College of William & Mary. This 3-year grant supports research to investigate the genetic basis of virulence traits in opportunistic fungal pathogens and how these traits may arise through "accidental virulence" or "coincidental selection" in the environment. The research will screen over 1,000...
The University of Southern California (USC) received a $623,986 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The funding supports a research project to study the genetic and molecular mechanisms that enable fungi, specifically the opportunistic pathogen Saccharomyces cerevisiae, to persist and cause infections in mammalian hosts. Key objectives include: Identifying causal...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $689,068 to the University of Cincinnati to establish ex vivo growth systems for the fungal genus Pneumocystis, which causes a life-threatening pneumonia in immunodeficient individuals. The key objectives are to: 1) Use metabolomics and flux balance analysis to identify critical nutrients for growing the surrogate...
This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover and develop new, more potent antifungal therapies for treating invasive fungal infections such as cryptococcosis, candidiasis, and aspergillosis. The funding will support the continued screening of chemical libraries to identify lead compounds that selectively inhibit the fungal ceramide synthase 1...
This Project Grant award of $750,815, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research aimed at developing novel anti-infective strategies to treat pulmonary mucormycosis, a deadly invasive fungal infection. The key objectives are to: 1) examine the role of the host cell hypoxia-response pathway, specifically the protein ANGPTL4, in the pathogenesis of mucormycosis and explore its therapeutic...
This Project Grant award, with a total funding of $773,053, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research by The Washington University, a leading private research institution, to study the biosynthesis of β-1,6-glucan, a key component of the cell wall in the fungal pathogen Cryptococcus neoformans. The goal is to elucidate the mechanisms of cell wall synthesis...
MATURATION, GERMINATION, AND PATHOGENESIS OF CRYPTOCOCCUS SPORES - PROJECT SUMMARY/ABSTRACT WORLDWIDE, OVER A BILLION PEOPLE EACH YEAR EXPERIENCE HIGH MORBIDITY AND/OR MORTALITY FROM THE EFFECTS OF HUMAN FUNGAL PATHOGENS. PEOPLE WITH AIDS, CHEMOTHERAPY PATIENTS, AND TRANSPLANT RECIPIENTS ARE AT HIGHEST RISK OF ACQUIRING LIFE-THREATENING INFECTIONS, BUT MANY FUNGI ALSO CAUSE DISEASE IN APPARENTLY HEALTHY INDIVIDUALS. AMONG THESE IS THE SPORE-FORMING YEAST, CRYPTOCOCCUS, WHICH IS UBIQUITOUS IN THE ENVIRONMENT. LIKE MANY PATHOGENIC FUNGI, CRYPTOCOCCUS CAUSES DISEASE WHEN IT IS INHALED INTO THE LUNG. FROM THE LUNG CRYPTOCOCCUS CAN DISSEMINATE TO THE CENTRAL NERVOUS SYSTEM (CNS) AND CAUSE FUNGAL MENINGOENCEPHALITIS THAT IS FATAL ~25% OF THE TIME, EVEN WITH STATE-OF-THE-ART TREATMENTS. IN THE UNITED STATES THE CASE MORTALITY RATE OVERALL FROM INVASIVE FUNGAL DISEASES IS ~50%, INDICATING THE DIRE NEED FOR IMPROVED THERAPEUTIC STRATEGIES. TO DEVELOP NEW ANTIFUNGAL THERAPEUTICS, WE NEED TO IDENTIFY NOVEL FUNGAL-SPECIFIC MOLECULES OR PATHWAYS. THUS, IT IS IMPERATIVE THAT WE GAIN A BETTER UNDERSTANDING OF THE FUNDAMENTAL BIOLOGY OF PATHOGENIC FUNGI, ESPECIALLY THE DEVELOPMENT AND GROWTH OF SPORES. OUR LONG-TERM RESEARCH GOAL IS TO UNDERSTAND HOW INFECTIOUS SPORES SURVIVE IN NEW ENVIRONMENTS, INCLUDING THE MAMMALIAN LUNG, AND USE THAT INFORMATION TO IDENTIFY FUNGAL-SPECIFIC TARGETS FOR THERAPEUTIC INTERVENTIONS. TO ACCOMPLISH THIS GOAL, WE HAVE DEVELOPED THE CRYPTOCOCCUS SYSTEM AS A MODEL FOR THE STUDY OF INFECTIOUS SPORES. THE OBJECTIVE OF THIS PROPOSED PROJECT IS TO DETERMINE THE MOLECULAR PROCESSES BY WHICH INFECTIOUS SPORES TRANSITION INTO VEGETATIVELY GROWING YEAST (GERMINATE) AND HOW THIS PROCESS INFLUENCES DISEASE. OUR OVERARCHING HYPOTHESIS IS THAT DETERMINING THE MOLECULAR MECHANISMS OF GERMINATION WILL IDENTIFY KEY PATHWAYS IN SPORE-MEDIATED INFECTIONS THAT CAN BE TARGETED FOR INHIBITION. TO TEST THIS HYPOTHESIS, WE WILL CARRY OUT THREE SPECIFIC AIMS: 1) DETERMINE THE MOLECULAR PATHWAYS AND PROCESSES REQUIRED FOR SPORE GERMINATION, 2) IDENTIFY THE MOLECULAR PROCESSES AND EVENTS THAT PROMOTE GERMINATION COMPETENCE OF SPORES, AND 3) DETERMINE THE EFFECTS OF SPORE GERMINATION KINETICS ON HOST-PATHOGEN INTERACTIONS AND DISEASE PROGRESSION. WE WILL COMBINE MOLECULAR AND CLASSICAL GENETICS, GENE EXPRESSION ANALYSES, CHEMICAL GENETICS, PROTEIN COMPOSITION ANALYSES, AND QUANTITATIVE GERMINATION ASSAYS TO REVEAL THE DEVELOPMENTAL AND REGULATORY MECHANISMS THAT FACILITATE SPORE SURVIVAL IN DIVERSE ENVIRONMENTS. AT THE SAME TIME, WE WILL USE IN VITRO TISSUE CULTURE MODELS AND A MOUSE INTRANASAL MODEL OF INFECTION TO DETERMINE HOW SPORES INFECT AND ESCAPE THE MAMMALIAN LUNG. THESE INNOVATIVE EXPERIMENTS WILL RESULT IN AN IN-DEPTH MAP OF SPORE PATHWAYS AND INSIGHTS INTO HOW SPORES INVADE THE HOST. UNDERSTANDING PATHWAYS AND PROCESSES ASSOCIATED WITH SPORE GERMINATION MAKES SIGNIFICANT CONTRIBUTIONS TO THE LONG-TERM OBJECTIVE OF THIS WORK TO IDENTIFY NEW AND DIVERSE MOLECULAR TARGETS THAT CAN BE EXPLOITED FOR NOVEL ANTIFUNGAL THERAPEUTICS AND STRATEGIES TO PREVENT AND/OR TREAT CRYPTOCOCCOSIS AND OTHER FATAL HUMAN FUNGAL DISEASES.